Market capitalization | $442.01m |
Enterprise Value | $456.37m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 13.22 |
P/S ratio (TTM) P/S ratio | 12.81 |
P/B ratio (TTM) P/B ratio | 13.20 |
Revenue growth (TTM) Revenue growth | 203.23% |
Revenue (TTM) Revenue | $34.51m |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
5 Analysts have issued a MeiraGTx Holdings plc forecast:
5 Analysts have issued a MeiraGTx Holdings plc forecast:
Mar '25 |
+/-
%
|
||
Revenue | 35 35 |
203%
203%
|
|
Gross Profit | -3.30 -3.30 |
30%
30%
|
|
EBITDA | -146 -146 |
6%
6%
|
EBIT (Operating Income) EBIT | -159 -159 |
5%
5%
|
Net Profit | -167 -167 |
126%
126%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
MeiraGTx Holdings Plc is a clinical-stage biotech company, which engages in the development of novel gene therapy treatments. It operates through the United States and United Kingdom geographical segments. Its pipeline includes AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1 and AAV-UPF1. The company was founded on March 20, 2015 and is headquartered in New York, NY.
Head office | Cayman Islands |
CEO | Alexandria Forbes |
Employees | 381 |
Founded | 2015 |
Website | www.meiragtx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.